BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 26729187)

  • 1. Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.
    van Es N; Bleker SM; Wilts IT; Porreca E; Di Nisio M
    Drugs; 2016 Mar; 76(3):331-41. PubMed ID: 26729187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline.
    Al-Hameed F; Al-Dorzi HM; AlMomen A; Algahtani F; AlZahrani H; AlSaleh K; AlSheef M; Owaidah T; Alhazzani W; Neumann I; Wiercioch W; Brozek J; Schünemann H; Akl EA
    Ann Saudi Med; 2015; 35(2):95-106. PubMed ID: 26336014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
    Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach.
    Pangilinan JM
    J Pharm Pract; 2010 Aug; 23(4):294-302. PubMed ID: 21507829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of anticoagulant treatment in cancer patients.
    Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
    Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
    Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
    Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of venous thromboembolism in patients with cancer.
    Prandoni P
    Intern Emerg Med; 2010 Oct; 5 Suppl 1():S27-30. PubMed ID: 20865471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses.
    Bleker SM; Buchmüller A; Chauleur C; Ní Áinle F; Donnelly J; Verhamme P; Jacobsen AF; Ganzevoort W; Prins M; Beyer-Westendorf J; DeSancho M; Konstantinides S; Pabinger I; Rodger M; Decousus H; Middeldorp S
    Thromb Res; 2016 Aug; 144():62-8. PubMed ID: 27289488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism.
    Barsam SJ; Patel R; Arya R
    Br J Haematol; 2013 Jun; 161(6):764-77. PubMed ID: 23560605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of deep vein thrombosis in cancer patients.
    Lee AY
    Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study.
    Figueroa R; Alfonso A; López-Picazo J; Gil-Bazo I; García-Mouriz A; Hermida J; Páramo JA; Lecumberri R
    PLoS One; 2018; 13(8):e0200220. PubMed ID: 30071038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.
    Lyman GH
    Cancer; 2009 Dec; 115(24):5637-50. PubMed ID: 19827150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.